LIN9 is a mitotic vulnerability in triple-negative breast cancer that is targetable with BET inhibitors.

被引：0
|
作者：
Sahni, J. M. [1 ]
Gayle, S. S. [1 ]
Webb, B. M. [1 ]
Weber-Bonk, K. L. [1 ]
Singh, S. [2 ]
Sizemore, S. T. [3 ]
Bebek, G. [4 ]
Varadan, V. [2 ]
Summers, M. K. [3 ]
Keri, R. A. [1 ,5 ,6 ]
机构：
[1] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
[3] Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 USA
[4] Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA
[5] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ, Dept Gen Med Sci Oncol, Cleveland, OH 44106 USA
来源：
MOLECULAR BIOLOGY OF THE CELL | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
P1270
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase
    Dmitry Malin
    Yoonkyu Lee
    Olga Chepikova
    Elena Strekalova
    Alexis Carlson
    Vincent L. Cryns
    Breast Cancer Research and Treatment, 2021, 190 : 373 - 387
  • [22] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [23] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    Clinical Pharmacokinetics, 2018, 57 : 427 - 437
  • [24] Anti-tumor activity of BET inhibitors in androgen-receptor- expressing triple-negative breast cancer
    Park, In Hae
    Yang, Han Na
    Jeon, Su Yeon
    Hwang, Jung-Ah
    Kim, Min Kyeong
    Kong, Sun-Young
    Shim, Sung Hoon
    Lee, Keun Seok
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer
    In Hae Park
    Han Na Yang
    Su Yeon Jeon
    Jung-Ah Hwang
    Min Kyeong Kim
    Sun-Young Kong
    Sung Hoon Shim
    Keun Seok Lee
    Scientific Reports, 9
  • [26] Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
    Nieto-Jimenez, Cristina
    Galan-Moya, Eva M.
    Corrales-Sanchez, Veronica
    del Mar Noblejas-Lopez, Maria
    Burgos, Miguel
    Domingo, Beatriz
    Montero, Juan Carlos
    Gomez-Juarez, Monica
    Granada Picazo-Martinez, Maria
    Esparis-Ogando, Azucena
    Pandiella, Atanasio
    Ocana, Alberto
    CANCER LETTERS, 2020, 491 : 50 - 59
  • [27] Identifying specific inhibitors of triple-negative breast cancer subtypes
    Robles, A. J.
    Cai, S.
    Du, L.
    Shaffer, C. V.
    Grkovic, T.
    Risinger, A. L.
    O'Keefe, B. R.
    Cichewicz, R. H.
    Mooberry, S. L.
    PLANTA MEDICA, 2016, 82
  • [28] Triple-Negative Breast Cancer
    Winkeljohn, Debra L.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (06) : 861 - 863
  • [29] Triple-Negative Breast Cancer
    Hudis, Clifford A.
    CANCER JOURNAL, 2010, 16 (01): : 10 - 11
  • [30] Triple-Negative Breast Cancer
    Quyen D. Chu
    King, Tari
    Hurd, Thelma
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
12345